BioSpace News Archive

MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting

Health Canada has authorized the use of the Pfizer-BioNTech Comirnaty COVID-19 vaccine as a booster shot.

Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in three investor conference events in November.

BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced the closing of the underwritten public offering of 2,300,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock at a per unit price of $10.00.

St. Jude Children’s Research Hospital® named its new 625,000 square-foot research facility the Inspiration4 Advanced Research Center in honor of Inspiration4, the world’s first all-civilian space mission to orbit Earth led by Jared Isaacman, CEO of Shift4 Payments.

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Design Therapeutics, Inc., a biotechnology company developing treatments for degenerative genetic disorders, reported recent pipeline progress and third quarter 2021 financial results.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, provided a corporate update and reported third quarter 2021 financial results.

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company focused on delivering genomic technologies for the advancement of science and medicine, today highlighted recent corporate achievements and reported financial results for the third quarter of 2021.